Our data showed that patients with low tumor stiffness had relatively higher immune cell infiltration, suggesting low LS is associated with a hot immune microenvironment phenotype, which might explain the differential responses to anti-PD-1–based therapy. The gene discussed is PDCD1; the disease is neoplasm.